GNLY and Schwartz-Jampel syndrome: However, if we face the clinical cases with a suspected diagnosis of SJS/TEN and there is a limitation to evaluate soluble Fas ligands and granulysin, especially due to the delayed sampling, other biomarkers might be useful for the detection of SJS/TEN to predict the future clinical course in these patients of drug eruption.